Peptide Inhibitors Block Tight Junction Permeability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory and autoimmune diseases associated with biological barrier dysfunction, such as celiac disease and inflammatory bowel disease, are insufficient in effectively inhibiting increased permeability of biological barriers and the secretion of pro-inflammatory signals.
Innovation Solution
Development of compounds and pharmaceutical compositions that inhibit the secretion of signals causing increased permeability of biological barriers, specifically targeting lymphocytes exposed to lipopolysaccharide (LPS) and pepsin/trypsin-treated gliadin (PTG), and the use of peptide permeability inhibitors to block the paracellular passage of gluten-derived peptides across epithelial barriers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for inflammatory and autoimmune diseases, then disease management is provided, but they are insufficient in effectively inhibiting increased permeability of biological barriers and secretion of pro-inflammatory signals
Solution Approach 1:
The patent uses peptide inhibitors as intermediary substances that specifically bind to and block the interaction between pro-inflammatory signals (such as zonulin) and their receptors on epithelial cells. This intermediary mechanism prevents the harmful effect of increased permeability without requiring direct modification of the barrier structure itself, thereby resolving the contradiction between maintaining barrier integrity and treating underlying inflammatory conditions
2Adaptability or versatility
If tight junctions are opened in response to environmental stimuli, then physiological responses occur, but pathological events and inflammatory diseases are initiated
Solution Approach 1:
The patent applies preliminary anti-action by administering peptide inhibitors before environmental stimuli (such as gluten or bacteria) can trigger pathological tight junction opening. The inhibitors pre-block the signaling pathways that lead to excessive permeability, allowing physiological responses to proceed while preventing the transition to pathological states, thus resolving the contradiction between adaptability and harm prevention
3Object-generated harmful factors
If peptide permeability inhibitors are used to block paracellular passage, then permeability is reduced, but treatment complexity increases
Solution Approach 1:
The patent employs short peptide sequences (6-20 amino acids) that are simple in structure, easy to synthesize, and can be produced cost-effectively. These short-lived peptide inhibitors are designed to be orally administrable and do not require complex delivery systems or long-term stability, thereby reducing treatment complexity while maintaining effectiveness in blocking paracellular passage of gluten-derived peptides
Data Source
AI summary
Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided. Methods for treating diseases relating to aberrant biological barrier permeability and peptide translocation across biological barriers are provided. Such diseases include celiac disease, necrotizing enterocolitis, diabetes, cancer, inflammatory bowel diseases, asthma, COPD, excessive or undesirable immune response, gluten sensitivity, gluten allergy, food allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, systemic lupus erythematosus, psoriasis, scleroderma and autoimmune thyroid diseases.